This webinar, held in English, provides valuable insights into the impact of the menstrual
cycle and hormonal contraception on ADHD, along with practical tools for managing care
and treatment during pregnancy.

The VDZ-cdst scoring system has been developed and tested through post-hoc analyses using data from over 3,000 patients...

Le Prof. A. Le Moine et le Dr T. Van Meerhaeghe, néphrologues à l'hôpital Erasme de Bruxelles, partagent leur expérience avec Livtencity 1 an après son lancement. 

Découvrez avec nous les derniers développements, les stratégies thérapeutiques et les perspectives dans la gestion du CMV après une transplantation.

Prof. Ann De Becker, hematologist at UZ Brussel, is sharing her experience with Livtencity 1 year after launch. 

Join us for the latest advancements, therapeutic strategies and insights in CMV management post-transplantation.

The European Conference on Infections in Leukaemia (ECIL) brings together experts in several fields to produce evidence-based recommendations from comprehensive literature reviews.  The 10th ECIL meeting in 2024 addressed new developments in CMV management after allogeneic HCT, and recommendations are presented in this Review.

Our medical experts have developed this in-depth overview of maribavir as a treatment option for refractory cytomegalovirus (CMV) infections in adult patients following hematopoietic stem cell transplantation (HSCT). 

Join Prof. Dr. Johan Maertens as he shares key insights and takeaways from the EBMT Congress 2024, held in Glasgow, UK. His discussion centers on infectious complications following CAR-T therapy and stem cell transplantation, with a particular focus on the management of cytomegalovirus infections.

Discover new innovative strategies for managing challenging CMV infections post-HSCT presented by Prof. Dr. Johan Maertens.

Prof. Dr. Johan Maertens shared an in-depth case study of a 59-year-old patient with acute leukemia who underwent haplo-identical stem cell transplantation. The patient faced a series of complex complications, including challenging CMV reactivations, renal impairment, myelotoxicity, and intercurrent bacteremias.

Prof. Dr. Nicholas Kneidinger, a renowned expert in lung transplantation from a lung transplantation center in Munich, shares insights from his extensive background in managing CMV. He discusses the newly introduced maribavir for treating resistant and refractory CMV infections, presenting two case studies of patients who underwent double lung transplants.